Clinical Trial Detail

NCT ID NCT02236013
Title A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Idarubicin

Gilteritinib

Age Groups: adult

No variant requirements are available.